Compared with other subtypes, the VIM‐dominant SCLC subtype was associated with abundant but functionally impaired CD4+ and CD8+ T‐cells, which highly expressed inhibitory checkpoints and potentially benefit from PD‐L1 blockade therapy. This evidence concerns the gene CD4 and small cell lung carcinoma.